Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Katherine V Hurst, John Matthew O’Callaghan & Ashok Handa. (2016) Risk impact of edoxaban in the management of stroke and venous thromboembolism. Vascular Health and Risk Management 12, pages 329-335.
Read now
Read now
Shant Shirvanian & Victor F. Tapson. (2015) Venous thromboembolism: identifying patients at risk and establishing prophylaxis. Current Medical Research and Opinion 31:12, pages 2297-2311.
Read now
Read now
Vivencio Barrios & Carlos Escobar. (2015) Edoxaban in the prevention and treatment of thromboembolic complications from a clinical point of view. Expert Review of Cardiovascular Therapy 13:7, pages 811-824.
Read now
Read now
Russell D. Hull & Meryl H. Gersh. (2015) The current landscape of treatment options for venous thromboembolism: a focus on novel oral anticoagulants. Current Medical Research and Opinion 31:2, pages 197-210.
Read now
Read now
Articles from other publishers (14)
Kuang-Tsu Yang, Wei-Chih Sun, Tzung-Jiun Tsai, Feng-Woei Tsay, Wen-Chi Chen & Jin-Shiung Cheng. (2020) The Risk of Gastrointestinal Bleeding between Non-Vitamin K Antagonist Oral Anticoagulants and Vitamin K Antagonists in the Asian Atrial Fibrillation Patients: A Meta-Analysis. International Journal of Environmental Research and Public Health 18:1, pages 137.
Crossref
Crossref
Kang-Ling Wang, Eng Soo Yap, Shinya Goto, Shu Zhang, Chung-Wah Siu & Chern-En Chiang. (2018) The diagnosis and treatment of venous thromboembolism in Asian patients. Thrombosis Journal 16:1.
Crossref
Crossref
Trang T. Vu & Melinda Gooderham. (2017) Adverse Drug Reactions and Cutaneous Manifestations Associated With Anticoagulation. Journal of Cutaneous Medicine and Surgery 21:6, pages 540-550.
Crossref
Crossref
Sandeep Devabhakthuni, Connie H. Yoon & Kathleen J. Pincus. (2016) Review of the Target-Specific Oral Anticoagulants in Development for the Treatment and Prevention of Venous Thromboembolism. Journal of Pharmacy Practice 29:4, pages 392-405.
Crossref
Crossref
Vivencio Barrios & Carlos Escobar. (2016) Implications of edoxaban in the prevention and treatment of thromboembolic complications in clinical practice. Future Cardiology 12:4, pages 419-433.
Crossref
Crossref
Ying He, Ian C. K. Wong, Xue Li, Shweta Anand, Wai K. Leung, Chung Wah Siu & Esther W. Chan. (2016) The association between non-vitamin K antagonist oral anticoagulants and gastrointestinal bleeding: a meta-analysis of observational studies. British Journal of Clinical Pharmacology 82:1, pages 285-300.
Crossref
Crossref
Erenie Guirguis, Dana Brown, Yasmin Grace, Dimple Patel & Samantha Henningfield. (2016) Establishing Edoxaban’s Role in Anticoagulation. Journal of Pharmacy Practice 29:3, pages 228-238.
Crossref
Crossref
Gregory Y.H. Lip, Stephen A. Mitchell, Xianchen Liu, Larry Z. Liu, Hemant Phatak, Sumesh Kachroo & Sarah Batson. (2016) Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. International Journal of Cardiology 204, pages 88-94.
Crossref
Crossref
Eduard Shantsila & Gregory YH LipEduard Shantsila & Gregory YH Lip. 2016. Non-Vitamin K Antagonist Oral Anticoagulants. Non-Vitamin K Antagonist Oral Anticoagulants
25
71
.
Mashio Nakamura, Norikazu Yamada & Masaaki Ito. (2015) Current management of venous thromboembolism in Japan: Current epidemiology and advances in anticoagulant therapy. Journal of Cardiology 66:6, pages 451-459.
Crossref
Crossref
Rupert Bauersachs. (2014) Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders. Clinical Investigation 4:7, pages 619-639.
Crossref
Crossref
Henri Bounameaux & A. John Camm. (2014) Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor. Drugs 74:11, pages 1209-1231.
Crossref
Crossref
Carl-Erik Dempfle. (2014) Direct Oral Anticoagulants—Pharmacology, Drug Interactions, and Side Effects. Seminars in Hematology 51:2, pages 89-97.
Crossref
Crossref
F.S. Czepluch, G. Hasenfuß & C. Jacobshagen. (2014) Neue Medikamente in der KardiologieNew pharmaceuticals in cardiology. Der Internist 55:4, pages 382-389.
Crossref
Crossref